Phase 2 Results from a Phase 1/2 Study of Tak-700 (ORTERONEL), An Oral, Investigational, Nonsteroidal 17,20-Lyase Inhibitor, with Docetaxel and Prednisone (DP) in Metastatic Castration-Resistant Prostate Cancer (MCRPC)
Year: 2012
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Authors: D.P. Petrylak, J.G. Gandhi, W.R. Clark, E.I. Heath, J. Lin, W.K. Oh, D.B. Agus, B. Carthon, S. Moran, G. Liu
Institutions: Columbia University Irving Medical Center, The Barbara Ann Karmanos Cancer Institute, Thomas Jefferson University, Mount Sinai Hospital, University of Southern California, Emory University, Winship Cancer Institute, Takeda Oncology (United States), University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2999753363